Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis

Dig Dis Sci. 2008 Jul;53(7):1988-93. doi: 10.1007/s10620-007-0003-2. Epub 2008 Apr 5.

Abstract

Statin treatment reduces hypercholesterolemia and may be anti-inflammatory. Case reports noted decreased alkaline phosphatase and histological improvement following statin treatment in primary biliary cirrhosis. The objective of this study was to assess the long-term effects of statin treatment in primary biliary cirrhosis. A retrospective analysis compared clinical and biochemical data from 15 hypercholesterolemic individuals with primary biliary cirrhosis who were treated long-term with atorvastatin with an age and gender matched, primary biliary cirrhosis control group. A significant decrease in total cholesterol and low-density lipoprotein (LDL)-cholesterol (p < or = 0.002) was observed throughout atorvastatin treatment (median time 2.5 years). LDL-cholesterol levels in the control group were not significantly changed after 2 years (p > 0.050). No significant changes were noted in alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin and Mayo Risk Score in either group (p > 0.05). Long-term atorvastatin treatment reduced LDL-cholesterol in primary biliary cirrhosis, but there was no evidence of any anti-inflammatory effect.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticholesteremic Agents / therapeutic use*
  • Atorvastatin
  • Female
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / drug therapy*
  • Lipids / blood
  • Liver Cirrhosis, Biliary / complications
  • Liver Cirrhosis, Biliary / drug therapy*
  • Liver Function Tests
  • Male
  • Middle Aged
  • Pyrroles / therapeutic use*
  • Quality of Life
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Heptanoic Acids
  • Lipids
  • Pyrroles
  • Atorvastatin